Esketamine for Depression


 

Pharmaceutical Trials in Depression

Background
MAPrc's Psychopharmacology team conducts trials of new medications for treating depression in partnership with pharmaceutical companies who develop and manufacture cutting edge new medicines. These trials are randomised controlled trials (RCT's) and provide participants with access to the latest treatments for depression under controlled and safe conditions. 

Aim 
The aim of randomised controlled trials is to validate the effectiveness of new medicines for treating depression.

Participants 
All randomised controlled trials (RCT's) have strict selection criteria to ensure the new medicine is trialled in specific subgroups of people, for example people with treatment resistent depression will require that the participant has trialled 2 or more existing treatments to be eligible to participate.

Methods 
Trials of the new medicine are usually randomised against a comparator medicine that has already been shown to be effective, or against a placebo. Participants will visit our clinic for an initial screening visit, and then if eligible, for a randomisation visit where they will be commenced on the new medicine or it's comparator. Participants will attend our clinic each week for a check up and to complete assessments of the treatmente effectiveness. Saftey testing is also completed at each visit. 

Participants are reimbursed between $30 - $40 for each visit to the clinic, and receive all medication free of charge.

To find out more about participating in one of our trials contact: participate.maprc@monash.edu

 

International study to predict optimised treatment - in depression (iSpotD)

Aim
An international phase IV effectiveness trial to identify genetic, neurophysiological and cognitive markers that predict specific response to the three most widely prescribed anti-depressant medications (Lexapro, Zoloft and Effexor) in major depression.
 
Participants
This study is currently recruiting participants who have depression.
 
Methods
People with depression will be randomly allocated to receive one of three approved and effective treatments: escitalopram, sertraline or venlafaxine.
 
Participants are involved in the study for approximately 1 year (52 weeks). There are two clinic visits (at baseline and week 8) during which genetic, cognitive and electrical brain function assessments will be conducted. Further, participants are contacted via phone for check ups.
 
Primary Researcher
Ms. Mirjana Stojkovic 
 
Recruitment for this study is now closed. 


 

 

 

 MAPrc Monash Alfred Psychiatry Research Centre, Level 4, 607 St Kilda Road, Melbourne 3004

 © MAPrc 2013. Designed and hosted by Infoxchange Australia